Impact of Neuropsychological Alteration of Decision-making Abilities on the Functioning of Patients With Eating Disorders
NEUROPSY_TCA
1 other identifier
interventional
340
1 country
1
Brief Summary
Eating disorders are multifactorial disorders currently conceptualized in a biopsychosocial model, but pathophysiology remains relatively unknown, and robust etiological models to guide treatment are therefore lacking. Different endophenotypes and neurocognitive vulnerability factors have been found in eating disorders including decision making abnormalities. The investigators hypothesize that decision making abnormalities are associated with a lower level of functioning and quality of life which could lead to social and interpersonal difficulties. The investigators also hypothesize that these anomalies are associated with a particular clinical profile (more restrictive profile, more hyperactivity, less insight on the disease and desire for care ...).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2017
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 3, 2017
CompletedFirst Submitted
Initial submission to the registry
May 11, 2017
CompletedFirst Posted
Study publicly available on registry
May 19, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2022
CompletedDecember 21, 2021
December 1, 2021
5.2 years
May 11, 2017
December 20, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Level of functional impairment assessed by the Work and Social Adjustment Scale (WSAS)
We aim to investigate the link between decision-making and daily functioning of patients with eating disorder.
Baseline
Secondary Outcomes (9)
Quality of life assessed by the Eating disorder quality of life (EDQOL) scale.
Baseline
Level of functional impairment assessed by the clinician with the Functional Assessment Staging Test (FAST) scale
Baseline
Quality of life assessed by the Eating disorder quality of life (EDQOL) scale.
Baseline
Level of functional impairment assessed by the clinician with the FAST scale
Baseline
Score to decision making test (Iowa gambling task)
At 12 months if patient is included in the ancillary study
- +4 more secondary outcomes
Study Arms (1)
Participants
OTHERAll participants performed the same evaluation: clinical and neuropsychological assessment. All of them are patients with an eating disorder.
Interventions
All patients assessed in the day-hospital will performed the same evaluation : * Blood sampling * Calorimetry * Osteodensitometry * Psychiatric assessment * Endocrinologic assessment * Dietetic assessment * Neuropsychological assessment * Self-questionnaires With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)
Eligibility Criteria
You may qualify if:
- Patient with an eating disorder according to Diagnostic and Statistical Manuel of Mental disorders-V (DSM-V) criteria
- Patient aged from 15 to 65 years
- Patient who performs the day-hospital evaluation
- Patient affiliated to a French social security system
- Patient able to understand the nature, the aim and the methodology of the study
- For minor one of the legal guardians gave his consent
You may not qualify if:
- Patient in an unstable somatic state (eg severe metabolic disorder making impossible or unreliable neuropsychological assessments)
- Patient's refusal to participate
- Patient on protective measures (guardianship or trusteeship)
- Pregnant or nursing women. A dosage of beta human chorionic gonadotropin (βHCG) will be performed to ensure the absence of pregnancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Lapeyronie
Montpellier, 34295, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2017
First Posted
May 19, 2017
Study Start
May 3, 2017
Primary Completion
July 30, 2022
Study Completion
July 30, 2022
Last Updated
December 21, 2021
Record last verified: 2021-12
Data Sharing
- IPD Sharing
- Will not share